SOUTH ORANGE, N.J.--(BUSINESS WIRE)--The Law Firm of Arons & Arons, LLC. has initiated an investigation of Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) on behalf of the company’s investors for possible violations of federal securities law.
Endo investors who would like to discuss this investigation and their legal options should contact Arons & Arons, LLC. (Jeffrey S. Arons, Esq.) at (973) 762-0795, or email us at firstname.lastname@example.org.
Endo reformulated Opana ER, an opiod painkiller in 2012. However, the U.S. Food and Drug administration has deemed Opana ER too dangerous for distribution. On June 8, 2017, the U.S. Food and Drug Administration (the “FDA”) instructed Endo to pull Opana ER off the U.S. market. According to the FDA the drug was pulled “due to the public health consequences of abuse”.
As a result, shares of Endo have fallen over 14% during intraday trading on June 9, 2017.
If you are an investor in Endo, or have information pertaining to this investigation, you are encouraged to contact Arons & Arons, LLC. (Jeffrey Arons, Esq.) at (973) 762-0795 or email us at email@example.com.
Arons & Arons, LLC, is a family oriented firm, that provides representation for individuals, including investors who have been victimized by securities fraud. Our attorneys understand the financial and emotional trauma that securities fraud can cause, and we are relentless in our efforts to hold corporate wrongdoers accountable and obtain compensation for our clients. For over 30 years our attorneys have provided personal, accessible, and effective legal representation for our clients.
This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.